TSHA news

Latest 2 stories · newest Jun 25, 2026

TSHA

Taysha Gene Therapies signs underwriting agreement for stock sale.

Taysha Gene Therapies agreed to sell 32.5 million shares of common stock and warrants to underwriters. The capital raising initiative is expected to provide liquidity to the company.

Offering Jun 25, 2026 sentiment 0.00 SEC filing ↗

TSHA

Taysha completes dosing in REVEAL pivotal trial for TSHA-102 Rett syndrome therapy

Taysha Gene Therapies completed enrollment of 17 patients in its REVEAL pivotal trial for TSHA-102, with 100% of Phase 1/2 Part A patients achieving developmental milestones and no serious adverse events reported. The company expects topline interim data and FDA feedback on BLA submission pathway in…

Regulatory Jun 22, 2026 sentiment +0.85 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same TSHA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/TSHA/newsSTART FREE